AstraZeneca presents cancer data as AstraZeneca stock trades at EUR 152.38

Published on 10/27/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Five pivotal Phase III trials headline the ESMO program. AstraZeneca stock costs EUR 152.38 on October 27, 2026 ahead of results on October 30.

ESMO portfolio reaches five trials

AstraZeneca's ESMO program covers five pivotal Phase III trials from October 23 to October 27, 2026.
The company is presenting more than 100 abstracts across oncology programs in October 2026.
AstraZeneca stock trades at EUR 152.38 at 9:01 a.m. CET at Lang & Schwarz on October 27, 2026.
AstraZeneca is scheduled to publish its nine-month and third-quarter 2026 results on October 30, 2026.

AstraZeneca, GB0009895292, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) is presenting data from five pivotal Phase III trials at the European Society for Medical Oncology Congress, while AstraZeneca stock was trading at EUR 152.38 at Lang & Schwarz at 9:01 a.m. CET on October 27, 2026. The company's AstraZeneca release dated October 19, 2026 says the program includes more than 100 abstracts and four Presidential Symposia.

Five trials carry the oncology message

The ESMO program spans gastric, lung and bladder cancer, giving investors a broad view of AstraZeneca's oncology pipeline rather than a single-product update. The company identifies CLARITY-Gastric01, SAFFRON, DeLLphi-305 and VOLGA among the featured Phase III studies, with the fifth pivotal trial also included in the congress program.

The schedule places several major presentations on October 24, October 25 and October 26, 2026. That concentration makes the congress an important clinical readout window before AstraZeneca reports its nine-month and third-quarter results.

What comes next for the stock

AstraZeneca's investor-relations calendar lists the ESMO Meet the Management event on October 26, 2026, followed by the company's nine-month and third-quarter 2026 results on October 30, 2026. The near-term investment debate therefore combines clinical progress with the next financial update.

Price remains a separate signal

The EUR 152.38 Lang & Schwarz indication gives the market a live German trading reference while the ESMO program supplies the company-specific catalyst. The current quotation does not by itself establish how investors will weigh clinical evidence against the upcoming results.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.